Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6123 Target Snapshot

Serine/threonine-protein kinase DCLK3 · SINGLE PROTEIN · Homo sapiens

286Compounds
106Assays
9Approved Drugs
137.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9C098. Use UniProt Q9C098 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9C098 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase DCLK3 as ChEMBL target CHEMBL6123, mapped to UniProt Q9C098. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase DCLK3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6123
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9C098
Serine/threonine-protein kinase DCLK3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase DCLK3 is the right protein anchor across sources, using UniProt Q9C098 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase DCLK3
UniProt AccessionQ9C098
Component TypeProtein
Sequence Length648 aa

Serine/threonine-protein kinase DCLK3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase DCLK3, mapped to UniProt Q9C098. Sequence length is 648 aa.

Mapped IDQ9C098
Review nameSerine/threonine-protein kinase DCLK3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

9
Approved
3
Phase III
6
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC508.0
KD129.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL221959 8.35 Kd 4.5 Approved
CHEMBL2103743 8.35 Kd 4.5 Approved
CHEMBL1287853 7.89 Kd 13.0 Approved
CHEMBL509032 7.85 Kd 14.0 Preclinical
CHEMBL388978 7.77 Kd 17.0 Preclinical
CHEMBL4465866 7.22 Kd 60.0 Preclinical
CHEMBL1908397 7.07 Kd 86.0 Preclinical
CHEMBL4576489 6.98 Kd 104.0 Preclinical
CHEMBL494089 6.96 Kd 110.0 Preclinical
CHEMBL535 6.96 Kd 110.0 Approved
Distribution

pChEMBL Value Distribution

6
5.0
14
5.5
8
6.0
8
6.5
2
7.0
6
7.5
3
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
NINTEDANIB
CHEMBL502835
Approved 2014
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

106
Total Assays
36
Tested Compounds
1
Assay Types
Binding — 106 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 83 32 6.4
assay format 19 1 5.8
cell-based format 4 3 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine